MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of “Hold” from Analysts

Shares of MaxCyte, Inc. (NASDAQ:MXCT) have been given an average rating of “Hold” by the five analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $5.50.

A number of research analysts have recently issued reports on the stock. Wall Street Zen cut shares of MaxCyte from a “hold” rating to a “sell” rating in a research note on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Finally, Craig Hallum lowered their target price on MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday.

Institutional Trading of MaxCyte

Hedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. acquired a new position in MaxCyte during the 2nd quarter worth $26,000. State of Wyoming bought a new stake in shares of MaxCyte during the second quarter worth $38,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of MaxCyte during the second quarter worth $40,000. Kwmg LLC lifted its stake in shares of MaxCyte by 75.8% during the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after acquiring an additional 11,135 shares during the period. Finally, Jain Global LLC bought a new position in MaxCyte in the fourth quarter valued at about $45,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $0.72 on Friday. The business’s fifty day moving average price is $0.85 and its two-hundred day moving average price is $1.32. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $2.96. The stock has a market capitalization of $77.12 million, a price-to-earnings ratio of -1.68 and a beta of 1.22.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. MaxCyte had a negative net margin of 135.14% and a negative return on equity of 21.60%. The business had revenue of $6.76 million for the quarter, compared to analyst estimates of $9.16 million. Research analysts expect that MaxCyte will post -0.42 EPS for the current fiscal year.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.